Cediranib
Cat. No.：YN440059
CAS No. ：288383-20-0
规格
价格(RMB)
库存
| 产品名称: | Cediranib |
| CAS No.: | 288383-20-0 |
| Chemical Name: | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-quinazoline |
| Synonyms: | 西地尼布; AZD2171 |
| 分子量: | 450.51 |
| 分子式: | C₂₅H₂₇FN₄O₃ |
| SMILES: | FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Cediranib (AZD2171) 是高选择性，有口服活性的VEGFR2抑制剂，对Flt1，KDR，Flt4，PDGFRα，PDGFRβ，c-Kit的IC50值分别为小于1， 小于3，5，5，36，2nM。 |
| IC50和靶点: | [{name:"Flt-1:5 nM (IC50)"},{name: "KDR:1 nM (IC50)"},{name: "Flt-4:3 nM (IC50)"},{name: "PDGFRα:36 nM (IC50)"},{name: "PDGFRβ:5 nM (IC50)"},{name: "c-Kit:2 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Rini, B.I.Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinomaCancer115(10 Suppl),2306-2312(2009)
Burger, R.A.Overview of anti-angiogenic agents in development for ovarian cancerGynecol. Oncol.121(1),230-238(2011)
Wedge, S.R., Kendrew, J., Hennequin, L.F., et al.AZD2171: A highly potent, orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerCancer Res.65(10),4389-4400(2005)
Davis, M.I., Hunt, J.P., Herrgard, S., et al.Comprehensive analysis of kinase inhibitor selectivityNat. Biotechnol.29(11),1046-1051(2011)
Bhargava, P., and Robinson, M.O.Development of second-generation VEGFR tyrosine kinase inhibitors: Current statusCurr. Oncol. Rep.13(2),103-111(2011)
Conti, A., Santoni, M., Amantini, C., et al.Progress of molecular targeted therapies for advanced renal cell carcinomaBiomed Res. Int.2013,419176(2013)
Castelli, C., Tazzari, M., Negri, T., et al.Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcomaJ. Transl. Med.11(1),237(2013)
